LDFR
SRPT icon

Lehman & Derafelo Financial Resources’s Sarepta Therapeutics SRPT Stock Holding History

Lehman & Derafelo Financial Resources’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-30,000
Closed -$4.21M – 268
2020
Q3 		$4.21M Buy
30,000
+20,000
+200% +$3.04M 1.34% 13
2020
Q2 		$1.6M Buy
+10,000
New +$1.36M 0.56% 37

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lehman & Derafelo Financial Resources's SRPT Position: Q4 2022 in Review

Lehman & Derafelo Financial Resources sold out of Sarepta Therapeutics (SRPT) in Q4 2022, closing a stake of 5,060 shares — an estimated $559K sold.

Lehman & Derafelo Financial Resources first reported a position in SRPT in Q4 2018 and held it in 13 quarters. The position peaked at $1.9M in Q4 2019. 411 funds tracked by Wall St. Rank hold SRPT as of Q4 2022.

  • Lehman & Derafelo Financial Resources reported no remaining Sarepta Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Lehman & Derafelo Financial Resources sold 5,060 Sarepta Therapeutics shares in Q4 2022, an estimated $559K.
  • Lehman & Derafelo Financial Resources first reported a position in Sarepta Therapeutics in Q4 2018 and held it in 13 quarters.
  • Lehman & Derafelo Financial Resources's Sarepta Therapeutics position peaked at $1.9M in Q4 2019.
  • 411 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2022.

Based on Lehman & Derafelo Financial Resources's 13F filing for Q4 2022, filed 20 Jan 2023.